Robert Wild, Ph.D.

Dr. Wild is a founding EIR with both Pandect Bioventures and Shangpharma Innovation. He is a visionary and strategic R&D executive with more than two decades of broad leadership experience in the pharmaceutical/biotech & venture capital industry including 13 years’ experience at the C-level across large pharma, mid-size public biotech and private entrepreneurial settings. Previously, Dr. Wild served as the Chief Scientific Officer and Co-Founder of Dracen Pharmaceuticals, Inc., a private biotechnology company developing novel oncology drugs in the field of immuno-metabolism. Prior to that, he served in various leadership roles including Chief Scientific Officer and Senior Vice President of Research at Ignyta, Inc. (NASDAQ: RXDX, acquired by Roche), Chief Scientific Officer Oncology Research at Eli Lilly & Company (NASDAQ: LLY), Senior Director Oncology Research at OSI Pharmaceuticals (NASDAQ: OSIP, acquired by Astellas Pharma), Senior Research Investigator at Bristol-Myers Squibb (NASDAQ: BMS) and Scientist at SUGEN, Inc. (acquired by Pfizer).

Dr. Wild has deep knowledge of the oncology drug discovery & development process spanning both small molecules and biologics. Throughout his career, Dr. Wild contributed to the discovery and translational research of more than 20 highly innovative oncology clinical development candidates including 5 FDA approved agents (Sutent®, Erbitux®, Sprycel®, Tarceva® and Rozlytrek^TM). He has an extensive track record in strategic planning, budgeting, R&D operations and contributed to public and private financings totaling >$130MM.

‍